5913-12-2

Upstream product

• 1356349-85-3 tert-butyl [(2S)-1-cyclohexylpropan-2-yl]carbamate 
• 54704-34-6 L-1-methyl-2-cyclohexylethylamine 
• 26226-49-3 1-methyl-2-cyclohexyl nitroethylene 
• 3938-96-3 ethyl 2-methoxyacetate 
• 60-15-1 2-amino-1-phenylpropane 
• 929117-24-8 2-[(1S)-2-cyclohexyl-1-methylethyl]-1H-isoindole-1,3(2H)-dione 
• 51-64-9 dexamfetamine 

Downstream Products

• 1356349-87-5 (2S)-1-cyclohexyl-N-(2-nitrobenzyl)propan-2-amine 
• 1356349-46-6 N-[2-({[(1S)-2-cyclohexyl-1-methylethyl]amino}methyl)phenyl]-8-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide 
• 1356349-89-7 tert-butyl [(2S)-1-cyclohexylpropan-2-yl](2-nitrobenzyl)carbamate 
• 925240-37-5 C₁₆H₂₅NO 
• 860641-77-6 N-(2-cyclohexyl-1-methyl-ethyl)-2-methylamino-acetamide 
• 876293-14-0 [((S)-2-Cyclohexyl-1-methyl-ethylcarbamoyl)-methyl]-methyl-carbamic acid benzyl ester 

Relevant academic research and scientific papers

HETEROCYCLIC SULFONAMIDES AS INHIBITORS OF TRANSFER RNA SYNTHETASE FOR USE AS ANTIBACTERIAL AGENTS

The present invention provides aromatic sulphonamides as tRNA synthetase inhibitors and process for their synthesis, pharmaceutical composition and method for treatment. Compounds disclosed can be used as antibacterial agents for the treatment or prevention of conditions caused by or contributed by aerobic and anaerobic Gram-positive pathogens, more particularly against bacterium, for example Staphylococcus, Enterococci and Streptococci. Compounds disclosed are used in particular for the treatment of skin and soft tissue infection, Formula (I)

Enzymatic enantiomeric resolution of phenylethylamines structurally related to amphetamine

Both enantiomers of several phenylethylamines, structurally related to amphetamine, have been prepared in good yields and excellent enantiomeric purity by enzymatic kinetic resolution using CAL-B and ethyl methoxyacetate as the acyl donor. In the case of the 4-hydroxyderivative of amphetamine (compound 4i), the S enantiomer racemized possibly in a dynamic kinetic resolution (DKR) under the enzymatic conditions used. The Royal Society of Chemistry 2011.

Acyclic cyanamide-based inhibitors of cathepsin K

Conversion of the proline-derived cyanamide lead to an acyclic cyanamide capable of forming an additional hydrogen bond with cathepsin K resulted in a large increase in inhibitory activity. An X-ray structure of a co-crystal of a cyanamide with cathepsin K confirmed the enzyme interaction. Furthermore, a representative acyclic cyanamide inhibitor 6r was able to attenuate bone resorption in the rat calvarial model.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.